GlassScriptPhysician profile
William J Mallon
NPI 1114976479
$4,834.57
in general payments reported to CMS, 2019-2025
35 companies · $451 in 2025
The $451 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $872 · 2020: $465 · 2021: $891 · 2022: $782 · 2023: $649 · 2024: $725 · 2025: $451.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,800 · Honoraria: $25.59.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,799.76 |
| Honoraria | $25.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ocular Therapeutix, INC. | $644.31 | 2021-2024 | Dextenza |
| Galderma Laboratories, L.P. | $606.50 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $482.93 | 2019-2025 | Eylea, Eylea Hd |
| Johnson & Johnson Surgical Vision, INC. | $299.05 | 2019-2025 | Veritas Vision System, Tecnis Iol |
| Novartis Pharmaceuticals Corporation | $259.52 | 2019-2023 | |
| Rxsight INC | $231.43 | 2022-2025 | Rxsight Injector Handpiece, Rxsight Light Delivery Device (Ldd), Rxsight Contact Lens |
| Alcon Vision LLC | $211.75 | 2019-2025 | Hydrus Microstent, Rocklatan |
| Abbvie INC. | $206.82 | 2022-2025 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $201.33 | 2019-2021 | |
| Bausch & Lomb Americas INC. | $195.92 | 2022-2025 | Miebo, Xiidra, Vyzulta |
| Allergan, INC. | $176.18 | 2019-2022 | |
| Omeros Corporation | $174.25 | 2019-2021 | |
| Tarsus Pharmaceuticals, INC. | $150.21 | 2024-2025 | Xdemvy |
| Horizon Therapeutics Plc | $112.08 | 2019-2022 | |
| Harrow Eye, LLC | $104.94 | 2024-2025 | Vevye, Iheezo |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Topcon Healthcare, INC. | $85.93 | 2019 | |
| Rayner Intraocular Lenses Limited | $73.27 | 2022 | |
| Dompe US, INC. | $70.88 | 2022-2024 | Oxervate |
| Kala Pharmaceuticals, INC. | $66.79 | 2021-2022 | |
| Oyster Point Pharma, INC. | $61.61 | 2022-2023 | Tyrvaya |
| Apellis Pharmaceuticals, INC. | $59.64 | 2022-2024 | Syfovre |
| Sun Pharmaceutical Industries INC. | $49.33 | 2021 | |
| Biotissue Holdings INC. | $39.25 | 2019-2023 | |
| Coopervision INC. | $29.97 | 2023 | Myday Contact Lens |
| Aerie Pharmaceuticals, INC. | $27.42 | 2020-2021 | |
| Sight Sciences, INC. | $25.54 | 2021 | |
| Mallinckrodt Hospital Products INC. | $24.46 | 2025 | Acthar |
| Eyepoint US, INC. | $24.39 | 2021 | |
| Pfizer INC. | $24.04 | 2024 | |
| Carl Zeiss Meditec Cataract Technology INC. | $22.06 | 2023 | |
| Johnson & Johnson Vision Care, INC. | $21.67 | 2024 | |
| Eyevance Pharmaceuticals LLC | $20.00 | 2020 | |
| Shire North American Group INC | $18.10 | 2019 | |
| Amgen INC. | $16.86 | 2024 | Tepezza |
| Glaukos Corporation | $16.14 | 2024 | Ce-Marked Kxla System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Mallon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.